Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has approved Cara Therapeutics Inc (NASDAQ:CARA) and Vifor Pharma AG’s Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney disease (CKD) undergoing dialysis.
- Difelikefalin is an opioid agonist that targets the kappa opioid receptor in the peripheral nervous system.
- The companies expect to launch Korsuva in Q1 of 2022 and hope to gain reimbursement and patient access through Medicare and Medicaid in 1H of 2022.
- Related content: Benzinga's Full FDA Calendar
- The nod was based on two Phase 3 studies of 1,300 CKD dialysis patients with moderate-to-severe pruritis, which showed that 40% and 37% of Korsuva recipients logged a four-point improvement from baseline on a measure of their most severe itch compared to 21% and 26% for those who received placebo.
- The drug’s data package included results from an additional 32 trials.
- Price Action: CARA shares are up 22.2% at $17.45 during the premarket session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!